PRGO · Perrigo

The thesis

Perrigo's shares are more likely to lag the S&P 500 than lead it. On 4 November 2026 the company cut 2026 core adjusted earnings-per-share guidance to $2.15–$2.35 from $2.25–$2.55. The Oral Care strategic review and the fourth-quarter report, expected around late February 2027, settle whether earnings and debt both improve.

The debt side moved less than the Infant Formula sale first suggests. The 29 October 2026 agreement with MeridianMade is worth up to $175 million, but only $40 million is cash at closing, and closing is expected in the first half of 2027. Total debt stood at about $3.3 billion on 26 September 2026, per the Form 10-Q.

The market has already looked past the cut. The shares closed at $16.55 on 11 November 2026, up 30.9% over three months, and above the $15.83 close on 4 November 2026, the day of the results release. That price reflects disposal progress and takeover talk more than the lower earnings range.

Bullish and bearish views on PERRIGO COMPANY PLC

The bull case on PERRIGO COMPANY PLC (PRGO), in brief: organic sales decline narrowed. The bear case: guidance fell on the like-for-like measure.

Bull case

• Organic sales decline narrowed. Third-quarter core organic net sales fell 1.1%, per the 4 November 2026 release, after a 3.5% fall in the second quarter. Core net sales were $908 million, down 1.7%.
• Cash flow improved in the quarter. Operating cash flow was $96 million in the third quarter, which brought the nine-month figure to $65.2 million from negative $31 million at the half. The 4 November 2026 release and the Form 10-Q report both numbers.
• A low-margin business is leaving. Infant Formula earned $8 million of segment adjusted operating income on $380 million of net sales in the four quarters to 27 June 2026, per the 29 October 2026 announcement. Perrigo expects the sale to lift margins and materially reduce future capital spending.
• Oral Care is still in play. The 4 November 2026 release says the strategic review of Oral Care remains ongoing. A sale with disclosed cash would add to the roughly $366 million of net business-sale proceeds reported for the first nine months.
• Takeover talk supports the shares. Betaville reported on 9 October 2026 that CVC Capital may be weighing a purchase. Perrigo has confirmed no approach, and the report is unconfirmed.

Bear case

• Guidance fell on the like-for-like measure. Core adjusted earnings-per-share guidance fell to $2.15–$2.35 on 4 November 2026. Core organic net-sales guidance moved to a decline of 2.7%–3.8%, from a range of a 3.0% decline to 1.0% growth. The release cites more measured retailer ordering before cough and cold season and continued softness in Europe.
• The sale brings little near-term cash. MeridianMade pays $40 million at closing, with up to $135 million contingent on net-sales milestones through 2030. Perrigo expects a non-cash impairment of $275–$375 million in the fourth quarter of 2026.
• Debt remains large. Long-term debt was $3,282.8 million and current debt $11.3 million against $436.6 million of cash on 26 September 2026, per the Form 10-Q. The 2026 outlook assumes net leverage of about 4.0 times adjusted earnings before interest, tax, depreciation and amortisation, and net interest expense of about $162 million.
• Dividends exceed operating cash flow so far. Cash dividends totalled $120.3 million in the first nine months of 2026, against $65.2 million of operating cash flow (Form 10-Q). Perrigo paid $0.29 a share in each quarter shown and declared another quarterly dividend on 29 October 2026.
• Main segments lost profit. Self Care adjusted operating income fell 19.4% to $105 million in the third quarter, and Specialty Care fell 24.2% to $32 million. The All Other segment rose 18.4% to $27 million with help from a tariff recovery.
• Write-downs and legal costs persist. The Form 10-Q shows a nine-month net loss of $351.6 million, $335.9 million of impairment charges, and a $61.0 million accrual for price-fixing lawsuits. Oral Care goodwill has been written down to zero after a $187.2 million impairment in 2026.
• Leadership remains interim. The 4 November 2026 release still names Albert Manzone as interim chief executive. A permanent appointee could change the disposal plan.

Price setup

The shares closed at $16.55 on 11 November 2026, 2.8% below the 52-week high of $17.02, reached intraday on 9 November 2026. They closed at $15.85 on 6 November 2026 and $16.95 on 9 November 2026, a rise that no Perrigo announcement accompanied. They then eased to $16.83 on 10 November 2026 and $16.55 on 11 November 2026.

The 50-day average is $15.09 and the 200-day average is $12.25, both as of 11 November 2026, so the shares trade above each. The 52-week closing low is $9.25, set on 20 March 2026. A close back below $15.83, the close on the day of the guidance cut, would erase the rebound that followed it.

Insider filings show routine activity only. SEC Form 4 filings from September 2026 record option exercises with shares withheld for tax by two directors and an executive vice president; none records an open-market sale or purchase. No Perrigo earnings date falls in the next 30 days.

Catalysts ahead

• ~25 February 2027 (est.): Fourth-quarter and full-year 2026 results; date not yet confirmed by Perrigo. Shows whether core adjusted earnings per share lands inside $2.15–$2.35, the size of the Infant Formula impairment, and whether debt fell.
• ~30 June 2027 (est.): Closing of the Infant Formula sale to MeridianMade by the first half of 2027, subject to customary conditions and regulatory approvals. Delivers the $40 million of upfront cash and removes a business with thin segment profit and heavy expected capital spending.
• ~31 March 2027 (est.): Outcome of the Oral Care strategic review; no date given by Perrigo. A sale with substantial cash would be the next real step in reducing about $3.3 billion of debt; no deal would remove that route.

What would change the view

A daily close above $18.37, well over the $17.02 52-week high set on 9 November 2026, which would show the shares leading the S&P 500 despite the guidance cut. A confirmed takeover offer, an Oral Care sale with substantial upfront cash, or 2026 core earnings guidance raised above $2.35 a share would also show the call wrong.

What it trades with

The shares trade mainly on company events: guidance, disposals and takeover reports. The 9 October 2026 CVC report and the 4 November 2026 guidance cut each moved them. The operating links are retailer ordering ahead of cough and cold season and the European consumer, both named in the 4 November 2026 release. Debt of about $3.3 billion and about $162 million of expected net interest expense also tie the equity to financing costs.